Skip to main content
Premium Trial:

Request an Annual Quote

CHA Selects Cepheid as Vendor of Choice for Molecular MRSA Tests

NEW YORK (GenomeWeb News) – Cepheid said yesterday that the Connecticut Hospital Association Shared Services Program for molecular surveillance of methicillin-resistant Staphylococcus aureus has selected Cepheid as its vendor of choice for the tests.
 
The CHA, which has 164 acute-care member hospitals, will exclusively market Cepheid’s GeneXpert Systems and Xpert MRSA test to its hospitals at pre-negotiated prices.
 
The program extends beyond Connecticut with member hospitals in eight other states including Massachusetts, Maine, Rhode Island, New Hampshire, Vermont, Illinois, Wyoming, and Iowa. Among these states, Illinois mandates surveillance of MRSA in hospitals, and legislation has been introduced in four of the other states for measures to prevent and control healthcare-associated infections, Cepheid said.
 
The CHA program includes hospitals with as few as 50 beds and as many as 800 beds, noted Rob Koska, Cepheid’s senior VP of worldwide commercial operations, in a statement.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.